Videos
Dr. Enrique Ocio presents an overview of Melflufen, an alkylating peptide belonging to Peptidase Enhanced Compounds (PEnCs) targeting the multiple myeloma (MM) transformation process through aminopeptidase potentiation of the compound. Melflufen in combination with dexamethasone (dex) has shown…
Videos
Relapsed/refractory (rel/ref) MM is associated with progressive immune dysfunction, including reversal of CD4:CD8 T cell ratio and acquisition of terminally-differentiated T cell phenotypes. BCMA-directed CAR T cells have promising activity in MM, but the factors that predict for robust in vivo…
Videos
Immunotherapy represents a new weapon in the fight against multiple myeloma. Current clinical outcomes using CAR-T cell therapy against multiple myeloma show promise in the eradication of the disease. However, these CARs observe relapse as a common phenomenon after treatment due to the reemergence…
Videos
Lenalidomide (LEN) until progressive disease (PD) is an established treatment (Tx) in newly diagnosed and relapsed and/or refractory multiple myeloma (RRMM); thus, patients (pts) for whom the benefit of LEN has been exhausted are a clinically relevant population. However, LEN-refractory pts have…
Videos
Elderly patients with newly diagnosed multiple myeloma (NDMM) are highly heterogeneous and their outcome is influenced by many factors: beside age, also comorbidities, general physical fitness, and cognitive function play a crucial role. The IMWG frailty score combines age, functional status, and…
Videos
Despite an array of approved agents for the treatment of multiple myeloma (MM), most patients eventually relapse after conventional treatments. The adoptive transfer of tumor-targeted T cells has demonstrated efficacy in the treatment of patients with chemo-refractory hematological malignancies…
Videos
F-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) is actually considered as the standard technique to assess and monitor the metabolic response to therapy and to define minimal residual disease (MRD) status outside the bone marrow (BM) in multiple…
Videos
Daratumumab (DARA) is a human IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action. DARA (16 mg/kg administered intravenously [IV]) is approved in many countries as monotherapy and in combination with standard of care (SOC) treatment regimens for…
Videos
Immunotherapy represents a new weapon in the fight against multiple myeloma. Current clinical outcomes using CAR-T cell therapy against multiple myeloma show promise in the eradication of the disease. However, these CARs observe relapse as a common phenomenon after treatment due to the reemergence…
Videos
Daratumumab (DARA) is a human, CD38-targeted, IgGκ monoclonal antibody. In the CASTOR study, D-Vd reduced the risk of disease progression or death by 68% and induced higher rates of deeper responses vs Vd in relapsed/refractory (RR) MM pts (Spencer, A. ASH 2017. Abs. 3145). Overall, in phase 3…
Videos
Daratumumab (DARA) is a human IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action. In combination with standard of care (SOC) regimens, DARA has consistently demonstrated a doubling of complete response (CR) rates, tripling of minimal residual disease…
Videos
Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs. Survival was poor particularly for high risk patients such as R-ISS stage III. The preliminary data from our center showed that the median PFS after auto-HSCT was 24 months for patients with R…
Videos
P-BCMA-101 is a novel chimeric antigen receptor (CAR)-T cell therapeutic targeting BCMA, which is highly expressed on MM cells. It is designed to increase efficacy while minimizing toxicity through reduced immunogenicity, lack of tonic signaling, a safety switch, and a product comprised…
Videos
Venetoclax (Ven), an oral agent that targets the antiapoptotic protein, BCL-2, has demonstrated efficacy, as monotherapy and combined with proteasome inhibitor (PI) bortezomib, in relapsed/refractory (R/R) multiple myeloma (MM). We report preliminary safety and efficacy data for Ven combined with…
Videos
Seeking AL Amyloidosis Very Early: The SAVE Trial - Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma
ABOUT RAYMOND L. COMENZO, MD
Dr. Raymond L. Comezo is the Director of Transfusion Services, John C. Davis Myeloma and Amyloid Program…
Videos
Carfilzomib lenalidomide and dexamethasone (KRd) is FDA-approved for the treatment relapsed/refractory multiple myeloma (RRMM) based on data from the ASPIRE study (Stewart K et al. NEJM 2015). Thalidomide, a first generation immunomodulatory drug (IMiD) is less costly than lenalidomide and is…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
**Due to technical problems during recording parts of the video may have no audio**
In this video, Dr. S. Vincent Rajkumar discusses…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
**Due to technical problems during recording parts of the video may have no audio**
Dr. Jesus F. San-Miguel discusses the advances in…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
**Due to technical problems during recording parts of the video may have no audio**
Drs. Shaji Kumar and Philippe Moreau discusses the…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
**Due to technical problems during recording parts of the video may have no audio**
In this video, Dr. Brian GM Durie discusses …
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
**Due to technical problems during recording parts of the video may have no audio**
In this video, Dr. S. Vincent Rajkumar discusses…
Videos
Join us for this year’s International Myeloma Foundation and Clinical Care Options cosponsored symposium, where an esteemed panel of international experts will offer their perspectives on practice-changing data and optimal management of patients with myeloma.
Interact with the experts as they…
Videos
In this week’s video, Dr. Brian G.M. Durie recommends what to do if the use of dexamethasone or other steroids cause adrenal insufficiency.
BOTTOM LINE:
If you have adrenal insufficiency issues due to steroid use, possibly consult with an endocrinologist to ensure your adrenal…
Videos
In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies.
BOTTOM LINE:
An important new combination…
News Article
Today, the Association of Fundraising Professionals (AFP) — Greater San Fernando Valley Chapter — commemorates National Philanthropy Day®. On this day, the AFP recognizes and pays tribute to the contributions that philanthropy — and philanthropists — have made to the community in the San Fernando…
Videos
In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.
BOTTOM LINE:
The FDA approval of once-weekly dosing of Kyprolis is effective, more…
Videos
click on the image above to watch the teleconference
(to view the teleconference in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This teleconference will provide an overview of clinical trials and their importance in medicine. Issues addressed will…
Videos
>
In this week’s video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back to the myeloma community.
BOTTOM LINE:
The Myeloma Warrior Spirit means having the energy and resilience to seek out the…
Page
Welcome to the Myeloma Manager™ Personal Care Assistant™. We are pleased to be able to offer this software, designed specifically for patients and caregivers battling multiple myeloma. The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers…
Videos
click on the image above to watch the teleconference
(to view the teleconference in fullscreen, click on the bottom right square icon underneath the YouTube logo)
Veterans Against Myeloma held a live webinar on the Blue Water Navy Vietnam Veterans Act of 2017. This legislation has been…
Videos
In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials to treat myeloma.
BOTTOM LINE:
Bispecific antibodies are showing great promise in clinical trials.
Page
Improving Lives, Finding the Cure: Your go-to source
The IMF produces and maintains an extensive library of publications and periodicals for patients and caregivers, as well as for healthcare professionals. All IMF publications are always free of charge and are available to download by clicking…
News Article
The International Myeloma Foundation 12th Annual Comedy Celebration opened with a video of Ray Romano passing the torch of being the event’s host to Kevin Nealon. In the video, Ray said that he had been hosting this comedy celebration since his twin boys were 12. Now his boys are 25, and Ray joked…
Videos
In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF).
BOTTOM LINE:
The FDA approval of the NGS test for MRD is excellent news, but this…
Videos
click on the image above to watch the teleconference
(to view the teleconference in fullscreen, click on the bottom right square icon underneath the YouTube logo)
Did you know that what you eat can sometimes impact side effects experienced with myeloma and/or the various treatment…
IMF Person
Rafi Stephan comes to the IMF from the world of entertainment, where he last served as an executive assistant in International Television Distribution at Warner Brothers. He was at Warner Brothers from 2006 to 2014, during which time he also served as special events director for the business…
IMF Person
Robin Tuohy - Vice President, Patient Support
25-Year Care Partner | Advocate | Support Group Leader
Robin has been a passionate and dedicated advocate in the myeloma community for 25 years. Her journey began in 2000 when her husband was diagnosed with myeloma at…
IMF Person
Miko Santos has extensive experience in mass media and news organizations. A graduate of De La Salle University, he holds a dual degree in Marketing and Behavioral Science. He started out as a photojournalist for Manila Times and Sun Star, covering everything from community events to coups d'etat…
IMF Person
Selma has spent 30+ years working in the non-profit sector for organizations providing humanitarian services nationwide. She joined the IMF in 2009 and is currently the Sr. Director of Operations and Co-Leader of a Spanish MM Support Group. Selma is a native Californian, a mother, loves animals,…
IMF Person
Joy’s background in the field of entertainment includes working in client services at BFM Digital and at Shapeshifter Inc. She is a graduate of Eastern Michigan University in Ypsilanti with a degree in Film Studies and a minor in Art. She is an avid reader, writer, singer, and hiker.
IMF Person
Jim Needham is responsible for assisting the IMF with graphic design and production of the IMF's vast array of printed materials. He was born and raised in Southern California, graduated from UCLA in Design, and has worked in that field ever since. He is experienced as an art director, graphic…
IMF Person
For six years, Sapna Kumar served as the IMF's Manager, Marketing and Communications. She brings editorial expertise from the publishing industry, from roles at companies including McGraw-Hill, Pearson Education, and Encyclopedia Britannica. In 2021, she served as a Digital Learning Manager with…
IMF Person
Missy Klepetar graduated from Reed College. She joined the IMF in the fall of 2006 and became part of the InfoLine team during the summer of 2008. Missy says that working on the InfoLine is the most rewarding thing she has done in a professional realm, and she feels privileged to be able to help…
IMF Person
Paul Hewitt joined the IMF in 2001 and has been one of the IMF's InfoLine Coordinators since 2005. Paul is dedicated to helping patients and caregivers focus on putting a game plan in place to cope with life with multiple myeloma. That structure, coupled with the information the InfoLine provides,…
IMF Person
Kevin’s responsibilities include offering individualized website assistance to the large network of IMF-affiliated multiple myeloma support groups. He graduated from Cal Poly Pomona with a degree in Business – Computer Information Systems. Kevin has diverse hobby interests, including the culinary…
IMF Person
Marya Kazakova is the Senior Director, Editor-in-Chief of Publications.
IMF Person
Danielle Doheny joined IMF after a six-year career on Capitol Hill where she worked as an adviser to two members of Congress. As a Congressional staffer, Danielle’s primary focus was on healthcare and issues related to energy, the environment, science, and technology. In her role with the IMF, she…